Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010

NEXT STORY
SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies
PREV STORY
Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010

NEXT STORY
SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies
PREV STORY
Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aravive Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Corporate Updates

author_avatar
NASDAQ Market News

SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

author_avatar
NASDAQ Market News

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018

Initiated a Phase 1 trial of SRF231, a fully human antibody targeting CD47 Completed ...

author_avatar
NASDAQ Market News